Telitacicept versus belimumab in proliferative lupus nephritis. [PDF]
Front ImmunolWang C +6 more
europepmc +1 more source
Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis. [PDF]
Lupus Sci MedEgypto DC +6 more
europepmc +1 more source
Late-onset lupus nephritis: what is the evidence? [PDF]
Kidney Res Clin PractGreen S +3 more
europepmc +1 more source
Systematic Review of Trial Design and End Points in Lupus Nephritis. [PDF]
Kidney Int RepGiang S +9 more
europepmc +1 more source
Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study. [PDF]
Front ImmunolWang C +6 more
europepmc +1 more source
Urine Afamin as a biomarker of lupus nephritis. [PDF]
Front ImmunolLin S +7 more
europepmc +1 more source
Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress. [PDF]
Int J Mol MedXue M, Feng J, Mao X.
europepmc +1 more source
Albuminuria in Lupus Nephritis: the hidden threat to cardiovascular health. [PDF]
Rheumatol Adv PractColina-García JF +3 more
europepmc +1 more source
Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy. [PDF]
J Clin MedDoria A +6 more
europepmc +1 more source
Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis. [PDF]
Rheumatol TherWan X +5 more
europepmc +1 more source